References
- Strandberg TE, Vanhanen H, Tikkanen MJ. Effect of statin treatment on C-reactive protein in coronary patients. Lancet 1999; 353: 118–9
- Tracy RP. Inflammation markers and coronary heart disease. Curr Opin Lipidol 1999; 10: 435–41
- Libby P, Ridker PM. Novel inflammatory markers of coronary risk. Theory versus practice. Circulation 1999; 100: 1148–50
- Kluft C, De Maat MPM, Gevers Leuven JA, Potter van Loon BJ, Mohrschladt MF. Statins and C-reactive protein. Lancet 1999; 353: 1274
- Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 1999; 100: 230–5
- Ikeda U, Ito T, Shimada K. Statins and C-reactive protein. Lancet 1999; 353: 1274–75
- Faggiotto A, Paoletti R. Statins and blockers of the renin-angiotensin system. Vascular protection beyond their primary mode of action. Hypertension 1999; 34: 987–96
- Bellosta S, Ferri N, Bernini F, Paoletti R, Corsini A. Non-lipid-related effects of statins. Ann Med 2000; 32: 164–76
- Riepponen P, Marniemi J, Rautaoja T. Immunoturbidimetric determination of apolipoproteins A-1 and B in serum. Scand J Clin Lab Invest 1987; 47: 739–44
- Hak AE, Stehouwer CDA, Bots ML, Polderman KH, Schalkwijk CG, Westendorp ICD. Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women. Arterioscler Thromb Vasc Biol 1999; 19: 1986–91
- Koenig W, Sund M, Fröhlich M, Fischer H-G, Löwel H, Döring A. C-reactive protein, sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men. Circulation 1999; 99: 237–42
- Fernandez-Real J-M, Ricart W. Insulin resistance and inflammation in an evolutionary perspective: the contribution of cytokine genotype/phenotype to thriftiness. Diabetologia 1999; 42: 1367–74
- Pajkrt D, Doran JE, Koster F, Lerch PG, Arnet B, Van der Poll T. Anti-inflammatory effects of re-constituted high-density lipoprotein during human endotoxemia. J Exp Med 1996; 184: 1601–8
- Ettinger WH, Varma VK, Sorci-Thomas M, Parks JS, Sigmon RC, Smith TK. Cytokines decrease apolipo-protein accumulation in medium from Hep G2 cells. Arterioscler Thromb 1994; 14: 8–13
- Weber C, Erl W, Weber KSC, Weber PC. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J Am Coll Cardiol 1997; 30: 1212–7
- Zhang YX, Cliff WJ, Schoefl GI, Higgins G. Coronary C-reactive protein distribution: its relation to development of atherosclerosis. Atherosclerosis 1999; 145: 375–9